On July 28, 2021, Deep Genomics announced it had completed its $180 million Series C financing round, led by SoftBank Vision Fund 2. The capital raised will help expand the AI Workbench and scale its pipeline to 30 programs. This allows Deep Genomics to embark on a large-scale data generation effort across 100 genes to identify novel targets, mechanisms and preclinical programs. In addition, Deep Genomics plans to advance four programs into the clinic by 2023 and further establish its clinical development capabilities.
Deep Genomics uses AI and machine learning to program and prioritize transformational RNA therapeutics for genetic diseases.
Osler, Hoskin & Harcourt LLP advised Deep Genomics with a team consisting of Chad Bayne, Justin Dharamdial, Theresa Donkor and Tiye Traore (Emerging and High Growth Companies).